Imaging surveillance of differentiated thyroid cancer

Radiologic Clinics of North America

Volumn 49, Issue 3, 2011, Pages 473-487

  Johnson, Nathan A ^a   LeBeau, Shane O ^b   Tublin, Mitchell E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Differentiated thyroid cancer; Imaging; PET CT; Radioiodine; Sonography; Surveillance; Thyroglobulin

Indexed keywords

IODINE 131; THYROGLOBULIN;

ARTICLE; ASPIRATION BIOPSY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER SIZE; CANCER STAGING; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFERENTIATED THYROID CANCER; DISEASE FREE SURVIVAL; ECHOGRAPHY; HIGH RISK PATIENT; HUMAN; IMAGE ANALYSIS; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE METASTASIS; MINIMAL RESIDUAL DISEASE; NECK DISSECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT CANCER; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN BLOOD LEVEL; TUMOR BIOPSY; WHOLE BODY SCINTISCANNING;

EID: 79955767714     PISSN: 00338389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rcl.2011.02.008     Document Type: Review

References (69)

1. Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994, 97(5):418-428.
2. Hay I.D., Thompson G.B., Grant C.S., et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002, 26(8):879-885.
3. Pacini F., Molinaro E., Castagna M.G., et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003, 88(8):3668-3673.
4. Schlumberger M., Berg G., Cohen O., et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004, 150(2):105-112.
5. Torlontano M., Crocetti U., Augello G., et al. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. J Clin Endocrinol Metab 2006, 91(1):60-63.
6. Surveillance epidemiology and end results. Available at: Accessed September 1, 2010. http://www.seer.cancer/gov.
7. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
8. Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006, 295(18):2164-2167.
9. Zhu C., Zheng T., Kilfoy B.A., et al. A birth cohort analysis of the incidence of papillary thyroid cancer in the United States, 1973-2004. Thyroid 2009, 19(10):1061-1066.
10. Mazzaferri E.L., Robbins R.J., Spencer C.A., et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003, 88(4):1433-1441.
11. Kim T.Y., Kim W.B., Kim E.S., et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005, 90(3):1440-1445.
12. Hollowell J.G., Staehling N.W., Flanders W.D., et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002, 87(2):489-499.
13. Gorges R., Maniecki M., Jentzen W., et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol 2005, 153(1):49-55.
14. Rubello D., Casara D., Girelli M.E., et al. Clinical meaning of circulating antithyroglobulin antibodies in differentiated thyroid cancer: a prospective study. J Nucl Med 1992, 33(8):1478-1480.
15. Pujol P., Daures J.P., Nsakala N., et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996, 81(12):4318-4323.
16. Cooper D.S., Specker B., Ho M., et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998, 8(9):737-744.
17. Eustatia-Rutten C.F., Smit J.W., Romijn J.A., et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 2004, 61(1):61-74.
18. Kloos R.T., Mazzaferri E.L. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005, 90(9):5047-5057.
19. Dam H.Q., Kim S.M., Lin H.C., et al. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning. Radiology 2004, 232(2):527-533.
20. Silberstein E.B. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med 2007, 48(7):1043-1046.
21. Cooper D.S., Doherty G.M., Haugen B.R., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19(11):1167-1214.
22. Som P.M., Curtin H.D., Mancuso A.A. An imaging-based classification for the cervical nodes designed as an adjunct to recent clinically based nodal classifications. Arch Otolaryngol Head Neck Surg 1999, 125(4):388-396.
23. Simeone J.F., Daniels G.H., Hall D.A., et al. Sonography in the follow-up of 100 patients with thyroid carcinoma. AJR Am J Roentgenol 1987, 148(1):45-49.
24. Tublin M.E., Alexander J.M., Ogilvie J.B. Appearance of absorbable gelatin compressed sponge on early post-thyroidectomy neck sonography: a mimic of locally recurrent or residual thyroid carcinoma. J Ultrasound Med 2010, 29(1):117-120.
25. Ko M.S., Lee J.H., Shong Y.K., et al. Normal and abnormal sonographic findings at the thyroidectomy sites in postoperative patients with thyroid malignancy. AJR Am J Roentgenol 2010, 194(6):1596-1609.
26. Shin J.H., Han B.K., Ko E.Y., et al. Sonographic findings in the surgical bed after thyroidectomy: comparison of recurrent tumors and nonrecurrent lesions. J Ultrasound Med 2007, 26(10):1359-1366.
27. Kim J.H., Lee J.H., Shong Y.K., et al. Ultrasound features of suture granulomas in the thyroid bed after thyroidectomy for papillary thyroid carcinoma with an emphasis on their differentiation from locally recurrent thyroid carcinomas. Ultrasound Med Biol 2009, 35(9):1452-1457.
28. Rettenbacher T., Macheiner P., Hollerweger A., et al. Suture granulomas: sonography enables a correct preoperative diagnosis. Ultrasound Med Biol 2001, 27(3):343-350.
29. Wunderbaldinger P., Harisinghani M.G., Hahn P.F., et al. Cystic lymph node metastases in papillary thyroid carcinoma. AJR Am J Roentgenol 2002, 178(3):693-697.
30. Kessler A., Rappaport Y., Blank A., et al. Cystic appearance of cervical lymph nodes is characteristic of metastatic papillary thyroid carcinoma. J Clin Ultrasound 2003, 31(1):21-25.
31. Rosario P.W., de Faria S., Bicalho L., et al. Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med 2005, 24(10):1385-1389.
32. Kuna S.K., Bracic I., Tesic V., et al. Ultrasonographic differentiation of benign from malignant neck lymphadenopathy in thyroid cancer. J Ultrasound Med 2006, 25(12):1531-1537. [quiz: 1538-40].
33. Lee J.H., Lee H.K., Lee D.H., et al. Ultrasonographic findings of a newly detected nodule on the thyroid bed in postoperative patients for thyroid carcinoma: correlation with the results of ultrasonography-guided fine-needle aspiration biopsy. Clin Imaging 2007, 31(2):109-113.
34. Sohn Y.M., Kwak J.Y., Kim E.K., et al. Diagnostic approach for evaluation of lymph node metastasis from thyroid cancer using ultrasound and fine-needle aspiration biopsy. AJR Am J Roentgenol 2010, 194(1):38-43.
35. Park J.S., Son K.R., Na D.G., et al. Performance of preoperative sonographic staging of papillary thyroid carcinoma based on the sixth edition of the AJCC/UICC TNM classification system. AJR Am J Roentgenol 2009, 192(1):66-72.
36. Ahuja A.T., Ying M., Yuen H.Y., et al. Power Doppler sonography of metastatic nodes from papillary carcinoma of the thyroid. Clin Radiol 2001, 56(4):284-288.
37. Lyshchik A., Higashi T., Asato R., et al. Cervical lymph node metastases: diagnosis at sonoelastography-initial experience. Radiology 2007, 243(1):258-267.
38. Cignarelli M., Ambrosi A., Marino A., et al. Diagnostic utility of thyroglobulin detection in fine-needle aspiration of cervical cystic metastatic lymph nodes from papillary thyroid cancer with negative cytology. Thyroid 2003, 13(12):1163-1167.
39. Baskin H.J. Detection of recurrent papillary thyroid carcinoma by thyroglobulin assessment in the needle washout after fine-needle aspiration of suspicious lymph nodes. Thyroid 2004, 14(11):959-963.
40. Uruno T., Miyauchi A., Shimizu K., et al. Usefulness of thyroglobulin measurement in fine-needle aspiration biopsy specimens for diagnosing cervical lymph node metastasis in patients with papillary thyroid cancer. World J Surg 2005, 29(4):483-485.
41. Lewis B.D., Hay I.D., Charboneau J.W., et al. Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol 2002, 178(3):699-704.
42. Monchik J.M., Donatini G., Iannuccilli J., et al. Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. Ann Surg 2006, 244(2):296-304.
43. Lazar V., Bidart J.M., Caillou B., et al. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 1999, 84(9):3228-3234.
44. Wang W., Larson S.M., Fazzari M., et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000, 85(3):1107-1113.
45. Grunwald F., Kalicke T., Feine U., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999, 26(12):1547-1552.
46. Dietlein M., Scheidhauer K., Voth E., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997, 24(11):1342-1348.
47. Schluter B., Bohuslavizki K.H., Beyer W., et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001, 42(1):71-76.
48. Alzahrani A.S., Mohamed G.E., Al Rifai A., et al. Role of [18F]fluorodeoxyglucose positron emission tomography in follow-up of differentiated thyroid cancer. Endocr Pract 2006, 12(2):152-158.
49. Giammarile F., Hafdi Z., Bournaud C., et al. Is [18F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake?. Eur J Endocrinol 2003, 149(4):293-300.
50. Robbins R.J., Srivastava S., Shaha A., et al. Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. J Clin Endocrinol Metab 2004, 89(12):6010-6016.
51. Razfar A., Branstetter B.F., Christopoulos A., et al. Clinical usefulness of positron emission tomography-computed tomography in recurrent thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2010, 136(2):120-125.
52. Saab G., Driedger A.A., Pavlosky W., et al. Thyroid-stimulating hormone-stimulated fused positron emission tomography/computed tomography in the evaluation of recurrence in 131I-negative papillary thyroid carcinoma. Thyroid 2006, 16(3):267-272.
53. Shammas A., Degirmenci B., Mountz J.M., et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 2007, 48(2):221-226.
54. Nahas Z., Goldenberg D., Fakhry C., et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 2005, 115(2):237-243.
55. Palmedo H., Bucerius J., Joe A., et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006, 47(4):616-624.
56. Jeong H.S., Baek C.H., Son Y.I., et al. Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. Clin Endocrinol (Oxf) 2006, 65(3):402-407.
57. Pryma D.A., Schoder H., Gonen M., et al. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer patients. J Nucl Med 2006, 47(8):1260-1266.
58. Zoller M., Kohlfuerst S., Igerc I., et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?. Eur J Nucl Med Mol Imaging 2007, 34(4):487-495.
59. Takashima S., Takayama F., Wang J., et al. Using MR imaging to predict invasion of the recurrent laryngeal nerve by thyroid carcinoma. AJR Am J Roentgenol 2003, 180(3):837-842.
60. Wang J.C., Takashima S., Takayama F., et al. Tracheal invasion by thyroid carcinoma: prediction using MR imaging. AJR Am J Roentgenol 2001, 177(4):929-936.
61. King A.D., Ahuja A.T., To E.W., et al. Staging papillary carcinoma of the thyroid: magnetic resonance imaging vs ultrasound of the neck. Clin Radiol 2000, 55(3):222-226.
62. Takashima S., Sone S., Takayama F., et al. Papillary thyroid carcinoma: MR diagnosis of lymph node metastasis. AJNR Am J Neuroradiol 1998, 19(3):509-513.
63. Gross N.D., Weissman J.L., Talbot J.M., et al. MRI detection of cervical metastasis from differentiated thyroid carcinoma. Laryngoscope 2001, 111(11 Pt 1):1905-1909.
64. Harach H.R., Franssila K.O., Wasenius V.M. Occult papillary carcinoma of the thyroid. A " normal" finding in Finland. A systematic autopsy study. Cancer 1985, 56(3):531-538.
65. Komorowski R.A., Hanson G.A. Occult thyroid pathology in the young adult: an autopsy study of 138 patients without clinical thyroid disease. Hum Pathol 1988, 19(6):689-696.
66. Kovacs G.L., Gonda G., Vadasz G., et al. Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake. Thyroid 2005, 15(2):152-157.
67. Ito Y., Uruno T., Nakano K., et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003, 13(4):381-387.
68. Ito Y., Tomoda C., Uruno T., et al. Ultrasonographically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma. World J Surg 2005, 29(7):917-920.
69. Ito Y., Tomoda C., Uruno T., et al. Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid. World J Surg 2006, 30(1):91-99.